Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

<p>Abstract</p> <p>Background</p> <p>Infection with HPV 16 and 18, the major causative agents of cervical cancer, can be prevented through vaccination with a bivalent or quadrivalent vaccine. Both vaccines provide cross-protection against HPV-types not included in the v...

Full description

Bibliographic Details
Main Authors: Westra Tjalke A, Stirbu-Wagner Irina, Dorsman Sara, Tutuhatunewa Eric D, de Vrij Edwin L, Nijman Hans W, Daemen Toos, Wilschut Jan C, Postma Maarten J
Format: Article
Language:English
Published: BMC 2013-02-01
Series:BMC Infectious Diseases
Subjects:
Cervical cancer
HPV-vaccination
Cost-effectiveness
Genital warts
Cross-protection
Pricing of vaccines
Online Access:http://www.biomedcentral.com/1471-2334/13/75

Internet

http://www.biomedcentral.com/1471-2334/13/75

Similar Items